The antibiotic vancomycin, recommended as first-line treatment for infection caused by the deadly superbug C. difficile (C. diff), may not be living up to its promise, according to new research. The ...

Clostridioides difficile/Clostridium difficile (C. diff) is a bacterial infection and is the most common cause of healthcare-associated diarrhea. C. diff has two distinct presentations, primary and ...

PENSACOLA, Fla. (WEAR) — Half a million people this year will get an infection called C. diff. It ranges from uncomfortable to life-threatening. And in more and more cases, doctors are turning to an ...

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the clostridium difficile treatment market and it is poised to grow by $ 159.87 mn during 2020-2024, progressing at a CAGR of about 5% during the ...

Researchers from the University of Virginia in Charlottesville have discovered a type of gut bacteria that could prove effective where other types of helpful bacteria have failed in the fight against ...

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

As Clostridium difficile creates a significant economic and morbidity burden for hospitals, researchers with Cleveland Clinic and the University of Texas School of Public Health in Houston sought to ...

Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

LONDON--(BUSINESS WIRE)--The global clostridium difficile treatment market size is expected to grow by USD 159.87 million as per Technavio. This marks a significant market growth compared to the 2019 ...

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the ...

DEAR DR. ROACH: I am a 76-year-old male who is in relatively good health. For the past six months, I have been experiencing ...

(Reuters) - Drugmakers racing to develop medicines and vaccines to combat a germ that ravages the gut and kills thousands have a new challenger: the human stool. For patients hit hardest by the ...